Nomar Lupron 4 Me said...
Didn't know about the Vitamin C issues. For years, my husband has taken tons of vitamin C and no other vitamins or supplements -- until his diagnosis 6 months ago. Now he takes Vit D, green tea, curcumin, resveratrol and several others.
Not a consensus by any means. These 2 directly contradict one anotherwww.dailymail.co.uk/health/article-2466592/Do-high-doses-vitamin-C-raise-prostate-cancer-risk.html
"The researchers linked high doses of vitamin C to an increased risk of lethal and advanced prostate cancer."www.cancer.gov/about-cancer/treatment/cam/patient/vitamin-c-pdq
"Laboratory studies have shown that high doses of vitamin C may slow the growth and spread of prostate, pancreatic, liver, colon, and other types of cancer cells.
Some laboratory and animal studies have shown that combining vitamin C with anticancer therapies may be helpful, while other studies have shown that certain forms of vitamin C may make chemotherapy less effective ..."scroll down to page 19(the page #s of the upper right hand corner of each page) or mine shows page 24 of 97 on the PDF counter):www.euro-med.us/dr-lasalvia-publications.pdf
looking for "Serum Markers Variation Consistent with Autoschizis Induced by Ascorbic Acid–Menadione in Patients with Prostate Cancer". Be sure to look at the graphs on page 22(or 27 on PDF counter)
Or here is the shorter abstract from PubMed:www.ncbi.nlm.nih.gov/pubmed/12665684
Med Oncol. 2003;20(1):45-52.
Serum markers variation consistent with autoschizis induced by ascorbic acid-menadione in patients with prostate cancer.
Lasalvia-Prisco E1, Cucchi S, Vázquez J, Lasalvia-Galante E, Golomar W, Gordon W.
1School of Medicine, University of Uraguay, Montevideo, Uriguay. firstname.lastname@example.org
In vitro exposure of malignant prostate cell lines to ascorbic acid-menadione showed that tumor cells were killed through a mechanism named autoschizis. Experimental animal studies showed that autoschizis is also evident when ascorbic acid-menadione is administered to nude mice with implanted human prostate tumors. Prostate-specific antigen (PSA) is a known serum marker of prostate tumor cells specific activity. Recently, total serum homocysteine has been identified as a marker of tumor cell numbers with sensitivity for early detection of tumor cell death induced by treatments. A clinical trial with prostate cancer patients submitted to the association of ascorbic acid-menadione was performed and PSA/homocysteine was assessed in the follow- up. The early response in serum PSA and homocysteine levels was reported. The results showed that ascorbic acid-menadione produced an immediate drop in tumor cell numbers as assessed by homocysteine levels. Serum PSA levels showed an early rise and later dropped. These results suggest that autoschizis can also be induced by this pharmacological association at the clinical level in prostate cancer patients. Further studies are being performed in order to research if these results can be found with other primary tumors as it was shown in in vitro and experimental models. Ascorbic acid-menadione could be emerging as a new antitumoral chemotherapy.
Here is a later study done with somewhat lower doses:www.ncbi.nlm.nih.gov/pmc/articles/PMC2288789/
Purpose: To evaluate the safety and efficacy of oral Apatone® (Vitamin C and Vitamin K3) administration in the treatment of prostate cancer in patients who failed standard therapy.
Materials and Methods: Seventeen patients with 2 successive rises in PSA after failure of standard local therapy were treated with (5,000 mg of VC and 50 mg of VK3 each day) for a period of 12 weeks. Prostate Specific Antigen (PSA) levels, PSA velocity (PSAV) and PSA doubling times (PSADT) were calculated before and during treatment at 6 week intervals. Following the initial 12 week trial, 15 of 17 patients opted to continue treatment for an additional period ranging from 6 to 24 months. PSA values were followed for these patients.
Results: At the conclusion of the 12 week treatment period, PSAV decreased and PSADT increased in 13 of 17 patients (p ≤ 0.05). There were no dose-limiting adverse effects. Of the 15 patients who continued on Apatone after 12 weeks, only 1 death occurred after 14 months of treatment.
Conclusion: Apatone showed promise in delaying biochemical progression in this group of end stage prostate cancer patients.
Keywords: Prostate, Prostate neoplasms, ascorbic acid, menadione, Vitamin K3, Apatone, Cancer............................
Following the 12 week trial, 15 of 17 patients opted to continue Apatone therapy. Any decision to remain on Apatone therapy was left entirely to the patient. Anecdotally, most patients reported feeling “better” and more “energetic.” This coupled with stabilization of rising PSA along with no significant side effects led the men to continue therapy. Four continued therapy for 6 months and 11 continued for at least 1 year with one patient continuing for more than 2 years. Therapy was not discontinued in any patient due to vitamin toxicity or for other safety reasons. The PSA values of these patients were checked at various intervals while on treatment and remained stable. Patients terminating Apatone therapy experienced sharp increases in PSA levels as seen in the linear spline fit analysis (Figure (Figure1).1). Of the 11 patients on therapy for greater than 1 year, only one (initial PSA 256, PSADT= 3 months, and PSAV 157ng/ml/yr) passed away after 14 months.
No noteworthy changes were observed in the patient's complete blood counts, biochemistry panels or coagulation studies. No dose limiting toxicity or adverse events were experienced. Mild intermittent gastro-esophageal reflux symptoms was observed in 16 of 17 patients, but was eliminated when the Apatone was taken with meals or with antacids.
So, yes, conflicting info out there about
Vitamin C, as usual. Although these are the only 2 human studies I have seen of the combination of Vitamin C and K, thus so far no conflicting studies on that, both indicate it is worthwhile. But there will probably be a conflicting study along shortly.